Evidence map›Paper›PMID 42054368›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.

Erika Testa, Clara Dezi, Francesca Lovat, Geny Piro, Carmine Carbone, Marina Capece, Giovanni Nigita, Erisa Putro, Elisabetta Di Renzi, Alessandra Simeone and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Erika Testa *Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome 00189, Italy.
Clara Dezi *Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome 00189, Italy.
Francesca LovatDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Geny PiroDepartment of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome 00136, Italy.
Carmine CarboneDepartment of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome 00136, Italy.
Marina CapeceDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Giovanni NigitaDepartment of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Erisa PutroDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome 00189, Italy.
Elisabetta Di RenziDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome 00189, Italy.
Alessandra SimeoneDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome 00189, Italy.
Luca Reggiani BonettiDepartment of Diagnostic, Clinic and Public Health Medicine, University of Modena and Reggio Emilia, Modena 41100, Italy.
Roberto CirombellaDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome 00189, Italy.
Paolo MagistriSurgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena 41100, Italy.
Vincenzo CorboDepartment of Engineering for Innovation Medicine, University of Verona, Verona 37134, Italy.
Davide PasiniDepartment of Engineering for Innovation Medicine, University of Verona, Verona 37134, Italy.
Barbara BellettiDivision of Molecular Oncology, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, Aviano 33081, Italy.ORCID 0000-0003-2249-0285
Gustavo BaldassarreDivision of Molecular Oncology, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, Aviano 33081, Italy.ORCID 0000-0002-9750-8825
Andrea VecchioneDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome 00189, Italy.
Carlo M Croce *Department of Cancer Biology and Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.ORCID 0000-0003-3788-1457
Gian Luca Rampioni Vinciguerra *Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome 00189, Italy.

Funding

Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 28801Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 30656
6 · The paper itself

Abstract

KRAS mutations are a hallmark of pancreatic ductal adenocarcinoma (PDAC), driving tumor initiation and progression in the vast majority of cases, with KRAS

Indexed as

Carcinoma, Pancreatic DuctalFos-Related Antigen-2Pancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMiceSignal TransductionTOR Serine-Threonine KinasesXenograft Model Antitumor AssaysFOSL2 protein, humanFos-Related Antigen-2KRAS protein, humanProto-Oncogene Proteins p21(ras)TOR Serine-Threonine KinasesFra-2KRAS inhibitorsMRTX-1133mTOR pathwaypancreatic cancer

Identifiers

PMID42054368
PMCPMC13142990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.